News | October 25, 2021
Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
At present 18 per cent of the local pharmaceutical market is under government's price control
The company to receive upfront and milestone payments, in addition to royalties
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
